The Alzheimer's Association International Conference (AAIC) 2026 featured significant advances in neuropsychology and cognitive assessment, highlighting new cognitive tests, digital cognitive assessments, and validation studies. This page captures the key developments presented at the conference.
AAIC 2026 showcased significant progress in digital cognitive assessment tools:
- Smartphone-based cognitive testing — attention, memory, and processing speed assessments administered via mobile applications
- Remote monitoring capabilities — enabling continuous cognitive tracking between clinical visits
- High correlation between smartphone cognitive tests and standard neuropsychological assessments
- Sensitivity to early cognitive changes in preclinical AD
Research presented by Kaye et al. and Doraiswamy et al. demonstrated the validity of digital cognitive assessments for early detection of mild cognitive impairment (Kaye et al., 2014; Doraiswamy et al., 2022).
New frameworks for detecting subtle cognitive changes were presented:
- Valid assessment approaches for identifying Objective Subtle Cognitive Difficulties
- Technology-enabled cognitive assessment including smartphone-based testing
- Integration with biomarker panels for enhanced prediction of cognitive decline
Research highlighted the integration of cognitive assessments with biomarker data:
- Blood + brief cognitive assessments combined for improved prediction
- Correlation between fluid biomarkers (p-Tau217) and cognitive performance
- Smartwatch data improving prediction of cognitive decline
- Smartphone-based cognitive assessments correlating with fluid biomarkers
Cognitive assessments in clinical trials are evolving:
- Remote monitoring and cognitive assessments as digital endpoints
- More frequent assessment between clinic visits
- Remote pre-screening to improve trial enrollment efficiency
- Interim monitoring tools supplementing traditional measures
Several novel cognitive testing approaches were highlighted:
- 5 Digit Cognitive Test: A smartphone-based assessment for early detection of MCI
- Computerized cognitive batteries with adaptive testing
- Ecological momentary assessment (EMA) for capturing naturalistic cognitive fluctuations
New neuropsychological criteria for mild cognitive impairment were discussed:
- Empirically-derived cutoff scores for various cognitive domains
- Sensitivity and specificity considerations
- Integration with ATN (Amyloid, Tau, Neurodegeneration) biomarker framework
¶ Domain-Specific Assessment
Research emphasized domain-specific cognitive testing:
| Cognitive Domain |
Key Advances |
Clinical Application |
| Episodic Memory |
Enhanced recall paradigms |
Early AD detection |
| Executive Function |
Digital trail-making tests |
FTD, vascular dementia |
| Processing Speed |
Computerized assessment |
Prevention trials |
AAIC 2026 featured validation studies addressing:
- Cultural and educational bias in cognitive testing
- Development of culturally appropriate assessment tools
- Multilingual cognitive assessment batteries
¶ Reliability and Reproducibility
Key validation metrics presented:
- Test-retest reliability for digital cognitive assessments
- Inter-rater reliability for clinician-administered tests
- Equivalence between in-person and remote administration
- Passive digital biomarkers: Typing patterns, smartphone usage behavior, GPS mobility patterns correlating with cognitive status
- Continuous glucose monitoring integrated with cognitive assessments
- Accelerometer data predicting cognitive decline risk
- FDA clearance pathways for digital cognitive assessments
- Biomarker-guided cognitive assessment stratification
- Personalized cognitive testing protocols
- Integration with digital phenotype data
- Kaye J, et al. Unobtrusive measurement of daily computer use to detect mild cognitive impairment. Alzheimers Dement. 2014
- Doraiswamy PM, et al. 5 Digit Cognitive Test: A novel smartphone-based assessment for early detection of mild cognitive impairment. Alzheimers Dement. 2022
- Bondi MW, et al. Neuropsychological criteria for mild cognitive impairment. 2022